4种中草药及其复方抗马拉色菌体的外药敏实验

目的观察苦参、当归、侧柏叶和白鲜皮及观察苦参、当归、侧柏叶和白鲜皮、混合药液与主要有效成分对4株CBS马拉色菌标准株的体外抑菌效果。方法通过液基稀释法,用含橄榄油的液体培养基测定各药液对马拉色菌的抑制作用。结果最小抑菌浓度（MIC）由小到大排列分别为：白鲜碱、苦参碱、苦参、侧柏叶、氧化苦参碱、侧柏叶＋当归（二仙丸）、混合药液（侧柏叶＋当归＋苦参＋白鲜皮）、白鲜皮、二仙丸＋苦参、苦参＋白鲜皮、二仙丸＋白鲜皮、槲皮素、当归、阿魏酸。结论4种中草药及其混合药液、主要有效成分均有抑制马拉色菌的作用。     

辅酶Q10联合金凤丸对体外授精-胚胎移植患者卵巢功能及子宫内膜容受性的影响

目的:探讨辅酶Q10联合金凤丸对体外授精-胚胎移植患者卵巢功能及子宫内膜容受性的影响。方法:选择2017年7月～2017年10月接诊的185例体外授精-胚胎移植患者进行研究,通过随机数表法将其分为观察组(n=95)和对照组(n=90)。对照组采用金凤丸进行治疗,观察组在对照组的基础上加用辅酶Q10进行治疗。治疗后,比较两组血清卵泡刺激素(FSH)、促黄体生成素(LH)、睾酮(T)、雌二醇(E_2)、胰岛素(INS)、子宫内膜厚度、孕激素(P)水平、获卵数、受精率及妊娠率。结果:治疗后,两组患者血清FSH、LH、T、E_2、INS水平均较治疗前明显下降,且观察组以上指标水平均显著低于对照组(P0.05);两组患者子宫内膜厚度和血清P水平均较治疗前明显升高,且观察组以上指标均显著高于对照组(P0.05);两组患者获卵数无明显差异,观察组患者受精率、妊娠率均显著高于对照组(P0.05)。结论:辅酶Q10联合金凤丸可明显增加子宫内膜厚度,提高妊娠率。     

血府逐瘀汤联合四联疗法治疗Hp阳性慢性萎缩性胃炎的临床观察

目的:探究血府逐瘀汤联合四联疗法治疗幽门螺旋杆菌(Hp)阳性慢性萎缩性胃炎的效果。方法:回顾性分析2014年5月-2017年12月在我院进行诊治的80例Hp阳性慢性萎缩性胃炎患者的临床资料,按照其入院顺序经随机数字表分为研究组和对照组,每组各40例患者。其中,对照组患者采用四联疗法,研究组患者在对照组基础上联合血府逐瘀汤进行治疗,对比两组患者的Hp转阴率、治疗前后胃黏膜病理积分的变化情况、临床症状积分的变化情况和不良反应发生率。结果:治疗后,研究组患者的Hp转阴率[85.0%(34/40)]显著高于对照组[62.5%(25/40)](P0.05)。两组上腹痛、纳差、上腹胀、反酸、嗳气等临床症状积分以及胃黏膜萎缩、肠化、不典型增生等病理积分均显著低于治疗前(P0.05),且研究组以上指标均明显低于对照组(P0.05)。研究组患者的不良反应发生率[5.0%(2/40)]与对照组[12.5%(5/40)]无显著性差异(P0.05)。结论:血府逐瘀汤联合四联疗法治疗Hp阳性慢性萎缩性胃炎的效果显著优于单用四联疗法,其可有效改善患者的病变程度和临床症状,且无明显不良反应产生。     

经皮激光汽化术联合杜仲腰痛丸治疗腰椎间盘突出症的效果观察

目的:研究经皮激光汽化术联合杜仲腰痛丸治疗腰椎间盘突出症的临床效果。方法:选择2016年4月~2018年4月我院脊柱骨科收治的106例腰椎间盘突出症患者,随机分为两组。对照组单独采用经皮激光汽化术治疗,观察组联合口服杜仲腰痛丸治疗,每次8粒,每天3次。比较两组的治疗有效率,治疗前后的VAS评分、JOA评分,血清白介素-1β(IL-1β)、肿瘤坏死因子-α(TNF-α)水平的改变情况。结果:治疗后,观察组的治疗有效率为88.68%(47/53),明显高于对照组[73.58%(39/53)](P0.05)。两组治疗后的VAS评分值均较治疗前明显降低(P0.05),JOA评分值均较对照组明显升高(P0.05),且观察组VAS评分值明显低于对照组,JOA评分值显著高于对照组(P0.05)。两组治疗后的血清IL-1β、TNF-α水平均较治疗前明显降低(P0.05),且观察组血清IL-1β、TNF-α水平明显低于对照组(P0.05)。两组均未发生神经损伤和无椎间盘炎等并发症。结论:经皮激光汽化术联合杜仲腰痛丸治疗腰椎间盘突出症的临床效果明显优于单独采用经皮激光汽化术治疗,其可以显著改善患者的生活质量,降低疼痛程度,其作用机制可能与有降低患者血清炎症介质IL-1β、TNF-α的表达有关。     

安宫牛黄丸原方及简方对脑出血大鼠损伤保护作用的研究

探讨安宫牛黄原方及简方对脑出血大鼠的保护作用,寻找更合理的组方。方法:采用胶原酶尾状核注射法造模,观察安宫牛黄丸原方及简方对脑出血损伤大鼠脑组织匀浆中超氧化物歧化酶(SOD)、丙二醛(MDA)含量的影响。结果:安宫牛黄原方及简方能不同程度的降低谷氨酸损伤神经元MDA含量,提高SOD的活性。结论:安宫牛黄丸全方及简方可在一定程度上通过抗氧化损伤来起到脑保护作用。     

越鞠丸石油醚提取物的气相色谱-质谱分析

采用气相色谱-质谱联用技术对中药复方越鞠丸石油醚提取物中的成分进行鉴定,共鉴定出60种成分,并采用峰面积归一化法确定了各成分的相对含量。     

Relationship satisfaction and outcome in women who meet their partner while using oral contraception

Hormonal variation over the menstrual cycle alters women's preferences for phenotypic indicators of men's genetic or parental quality. Hormonal contraceptives suppress these shifts, inducing different mate preference patterns among users and non-users. This raises the possibility that women using oral contraception (OC) choose different partners than they would do otherwise but, to date, we know neither whether these laboratory-measured effects are sufficient to exert real-world consequences, nor what these consequences would be. Here, we test for differences in relationship quality and survival between women who were using or not using OC when they chose the partner who fathered their first child. Women who used OC scored lower on measures of sexual satisfaction and partner attraction, experienced increasing sexual dissatisfaction during the relationship, and were more likely to be the one to initiate an eventual separation if it occurred. However, the same women were more satisfied with their partner's paternal provision, and thus had longer relationships and were less likely to separate. These effects are congruent with evolutionary predictions based on cyclical preference shifts. Our results demonstrate that widespread use of hormonal contraception may contribute to relationship outcome, with implications for human reproductive behaviour, family cohesion and quality of life.     

滋肾骨康丸治疗骨质疏松症的临床研究

目的：观察滋肾骨康丸治疗骨质疏松症的临床疗效,并对该药的作用机理进行探讨。方法：将60例病人随机分为治疗组（滋肾骨康丸组）及对照组（西药组）,根据2组骨密度、骨痛、中医证候结果及临床总体疗效为指标进行比较。结果：治疗组治疗后总有效率为95．8％,对照组治疗后总有效率为75．3％,差异有统计学意义（P〈0．01）;2组治疗前后骨密度无显著性差异（P〉0．05）;治疗组治疗后骨痛有效率为92．5％。优于对照组的7313％（P〈0．05）;治疗后治疗组中医证候有效率为100％,明显优于对照组的53.3％（P〈0．01）。结论：滋肾骨康丸能显著改善骨痛、肾虚证候,总体改善临床症状,具有较好的治疗作用,值得进一步推广。     

CONSCIENTIOUS OBJECTIONS IN PHARMACY PRACTICE IN GREAT BRITAIN

Pharmacists who refuse to provide certain services or treatment for reasons of conscience have been criticized for failing to fulfil their professional obligations. Currently, individual pharmacists in Great Britain can withhold services or treatment for moral or religious reasons, provided they refer the patient to an alternative source. The most high‐profile cases have concerned the refusal to supply emergency hormonal contraception, which will serve as an example in this article. I propose that the pharmacy profession's policy on conscientious objections should be altered slightly. Building on the work of Brock and Wicclair, I argue that conscientious refusals should be acceptable provided that the patient is informed of the service, the patient is redirected to an alternative source, the refusal does not cause an unreasonable burden to the patient, and the reasons for the refusal are based on the core values of the profession. Finally, I argue that a principled categorical refusal by an individual pharmacist is not morally permissible. I claim that, contrary to current practice, a pharmacist cannot legitimately claim universal exemption from providing a standard service, even if that service is available elsewhere.